Thomas McNerney & Partners LP

Thomas McNerney & Partners LP discloses dealings in 5 companies, chiefly Zogenix, Inc., Ocera Therapeutics, Inc. and Clarus Therapeutics Holdings, Inc. Between 18 May 2006 and 20 April 2022, the trades on record add up to 43 filings.

Market trades split into 9 purchases (€4.4M) and 12 sales (€17.5M). Sales outweigh purchases by €13.1M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2022, the count stands at no purchases and 12 sales.

Half of the purchases are above €17k and half below.

The newest entry dates from 25 April 2022: an open-market sale of €32k, in Clarus Therapeutics Holdings, Inc. The last insider purchase was made public on 6 April 2011, 5,679 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.